• HCM therapeutics market in EMEA
• HCM therapeutics market in APAC PART 11 : Decision framework PART 12 : Drivers and challenges
• Market drivers
• Market challenges
• Impact of drivers and challenges on key customer segments ( hospitals and pharmacies ) PART 13 : Market trends
• Increasing availability of genetic tests
• Development of TBI
• Advent of genomic medicine PART 14 : Vendor landscape
• Competitive landscape PART 15 : Key vendor analysis
• AstraZeneca
• Merck
• Pfizer
• Sanofi
• Other prominent vendors PART 16 : Appendix
• List of abbreviations List of Exhibits Exhibit 01 : Types of HCM Exhibit 02 : Treatment for HCM Exhibit 03 : Snapshot of HCM therapeutics pipeline 2016 Exhibit 04 : Pipeline analysis for HCM therapeutics market Exhibit 05 : Mutation Exhibit 06 : Identification of pathogenicity in genes by genetic testing Exhibit 07 : Global HCM therapeutics market snapshot Exhibit 08 : Global HCM therapeutics market 2016-2021 ($ millions ) Exhibit 09 : Opportunity analysis in global HCM therapeutics market Exhibit 10 : Five forces analysis Exhibit 11 : Market segmentation based on drug class Exhibit 12 : Global calcium channel blockers market 2016-2021 ($ millions ) Exhibit 13 : Global beta-adrenergic blockers market 2016-2021 ($ millions ) Exhibit 14 : Global antiarrhythmic market 2016-2021 ($ millions ) Exhibit 15 : Global anticoagulants market 2016-2021 ($ millions ) Exhibit 16 : Global HCM therapeutics market by geography 2016 and 2021 Exhibit 17 : Global HCM therapeutics market by geography 2016-2021 ($ millions ) Exhibit 18 : Market scenario in Americas Exhibit 19 : HCM therapeutics market in Americas 2016-2021 ($ millions ) Exhibit 20 : Market scenario in EMEA Exhibit 21 : HCM therapeutics market in EMEA 2016-2021 ($ millions ) Exhibit 22 : Market scenario in APAC Exhibit 23 : HCM therapeutics market in APAC 2016-2021 ($ millions ) Exhibit 24 : Prevalence of obesity among US adults 2015 Exhibit 25 : Impact of drivers and challenges Exhibit 26 : Group of HCM individuals based on genetic tests Exhibit 27 : Competitive structure analysis of global HCM therapeutics market 2016 Exhibit 28 : AstraZeneca : Key highlights